Kestra Medical Technologies (NASDAQ:KMTS) Earns Buy Rating from Analysts at Bank of America

Investment analysts at Bank of America started coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Bank of America‘s price objective points to a potential upside of 28.04% from the stock’s previous close.

A number of other brokerages also recently commented on KMTS. Wells Fargo & Company initiated coverage on Kestra Medical Technologies in a research note on Monday. They issued an “overweight” rating and a $28.00 target price on the stock. Wolfe Research began coverage on Kestra Medical Technologies in a report on Monday. They issued an “outperform” rating and a $29.00 price objective on the stock. Stifel Nicolaus started coverage on shares of Kestra Medical Technologies in a research report on Monday. They set a “buy” rating and a $28.00 price objective on the stock. The Goldman Sachs Group assumed coverage on shares of Kestra Medical Technologies in a research report on Monday. They issued a “neutral” rating and a $24.00 target price for the company. Finally, Piper Sandler began coverage on shares of Kestra Medical Technologies in a report on Monday. They set an “overweight” rating and a $27.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Kestra Medical Technologies presently has an average rating of “Moderate Buy” and an average target price of $27.67.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies stock opened at $23.43 on Monday. Kestra Medical Technologies has a 12 month low of $20.00 and a 12 month high of $25.98.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.